XSHE
002020
Market cap1.50bUSD
Oct 09, Last price
11.87CNY
1D
1.45%
1Q
-17.11%
Jan 2017
25.83%
IPO
469.76%
Name
Zhejiang Jingxin Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Jingxin Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the full spectrum of pharmaceutical activities, from research and development to manufacturing and sales within the country. Its diverse product line includes active pharmaceutical ingredients (APIs), along with a wide array of finished medications such as antihypertensives, various antibiotics (including quinolones and cephalosporins), gastrointestinal remedies, antidiabetics, antipileptics, antihistamines, H+ pump inhibitors, H2 receptor blockers, cholesterol-lowering drugs, and antidepressants, as well as biopharmaceutical products. Additionally, the company is a provider of advanced medical display solutions, offering diagnostic, surgical, clinical, large-screen, integrated, and ultrasonic medical displays. Originally founded in 1974 as Zhejiang Jingxin Pharmaceutical Factory, the company officially rebranded to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000 and maintains its headquarters in Xinchang, China.
Key people
Gang Lu
Chairman of the Board, President · since 2023
Meili Chen
Chief Financial Officer, Vice President, Director · since 2023
Sheng Liu
Vice President, Chief Procurement Officer
Junmin Wang
Vice President · since 2023
Zhibin Zhu
Vice President · since 2022
Yunfei Hong
Secretary of the Board, Director of Strategic Development, Director · since 2022
Jian Hou
Director
Wan Hu
Director · since 2022
Bixiang Li
Director · since 2025
Jiaqi Lu
Director · since 2025
Nengneng Wang
Vice Chairman of the Board, Vice President · since 2025
Xiaojun Xu
Staff Elected Director · since 2025
Independent Director · since 2025
Independent Director · since 2022
Weiyue Lu
Independent Director
Independent Director · since 2022
Daliang Zhang
Independent Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||